Menka Khoobchandani

Menka Khoobchandani

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2017 in Dalton Transactions
Verified
Journal Article
Closed access
PDF file
AAA. Y. Al-Yasiri
A. Y. Al-Yasiri
MKMenka Khoobchandani
Menka Khoobchandani
CCC. S. Cutler
C. S. Cutler
LWL. Watkinson
L. Watkinson
TCT. Carmack
T. Carmack
Kattesh V KattiKattesh V Katti
Kattesh V Katti
We report here production of MGF-198AuNPs and its application for prostate tumor therapy.

Verified
Journal Article
Open access
PDF file
MKMenka Khoobchandani
Menka Khoobchandani
KKKavita Katti
Kavita Katti
AMAdam Maxwell
Adam Maxwell
WFWilliam P. Fay
William P. Fay
Kattesh V KattiKattesh V Katti
Kattesh V Katti
In our efforts to develop new approaches to treat and prevent human vascular diseases, we report herein our results on the proliferation and migration of human smooth muscles cells (SMCs) and endothelial cells (ECs) using epigallocatechin-3-gallate conjugated gold nanoparticles (EGCg-AuNPs) as possible alternatives to drug coated stents. Detailed in vitro stability studies of EGCg-AuNPs in various biological fluids, affinity and selectivity towards SMCs and ECs have been investigated. The EGCg-AuNPs showed selective inhibitory efficacy toward the migration of SMCs. However, the endothelial cells remained unaffected under similar experimental conditions. The cellular internalization studies have indicated that EGCg-AuNPs internalize into the SMCs and ECs within short periods of time through laminin receptor mediated endocytosis mode. Favorable toxicity profiles and selective affinity toward SMCs and ECs suggest that EGCg-AuNPs may provide attractive alternatives to drug coated stents and therefore offer new therapeutic approaches in treating cardiovascular diseases.

4 November 2018
Verified
Book Chapter
Closed access
PDF file
MKMenka Khoobchandani
Menka Khoobchandani
KKKavita K. Katti
Kavita K. Katti
AKAlice Raphael Karikachery
Alice Raphael Karikachery
VTVelaphi Thipe
Velaphi Thipe
PBPierce L. R. Bloebaum
Pierce L. R. Bloebaum
KKKattesh V. Katti
Kattesh V. Katti

Verified
Journal Article
Open access
PDF file
RSRosemeire Silva
Rosemeire Silva
RGRicardo J. Giordano
Ricardo J. Giordano
PGPaulo S. Gutierrez
Paulo S. Gutierrez
VRViviane Z. Rocha
Viviane Z. Rocha
MRMartina Rudnicki
Martina Rudnicki
JKJorge Kalil
Jorge Kalil
The purpose of our work was to select phages displaying peptides capable of binding to vascular markers present in human atheroma, and validate their capacity to target the vascular markers in vitro and in low-density lipoprotein receptor knockout (LDLr−/−) mouse model of atherosclerosis. By peptide fingerprinting on human atherosclerotic tissues, we selected and isolated four different peptides sequences, which bind to atherosclerotic lesions and share significant similarity to known human proteins with prominent roles in atherosclerosis. The CTHRSSVVC-phage peptide displayed the strongest reactivity with human carotid atherosclerotic lesions (p < 0.05), when compared to tissues from normal carotid arteries. This peptide sequence shares similarity to a sequence present in the fifth scavenger receptor cysteine-rich (SRCR) domain of CD163, which appeared to bind to CD163, and subsequently, was internalized by macrophages. Moreover, the CTHRSSVVC-phage targets atherosclerotic lesions of a low-density lipoprotein receptor knockout (LDLr−/−) mouse model of atherosclerosis in vivo to High-Fat diet group versus Control group. Tetraazacyclododecane-1,4,7,10-tetraacetic acid-CTHRSSVVC peptide (DOTA-CTHRSSVVC) was synthesized and labeled with 111InCl3 in >95% yield as determined by high performance liquid chromatography (HPLC), to validate the binding of the peptide in atherosclerotic plaque specimens. The results supported our hypothesis that CTHRSSVVC peptide has a remarkable sequence for the development of theranostics approaches in the treatment of atherosclerosis and other diseases.

18 August 2018 in Preprints.org
Verified
Preprint
Open access
TSTamer Sakr
Tamer Sakr
SMSherine A. G. Morsy
Sherine A. G. Morsy
NMNourhan A. Mahmoud
Nourhan A. Mahmoud
HRHassan M. Rashed
Hassan M. Rashed
HEH. A. Abd El-Rehim
H. A. Abd El-Rehim
KKKattesh V. Katti
Kattesh V. Katti
Gold nanoparticles are currently used for the treatment of cancer through a myriad of modalities and delivery approaches. Conjugation of tumor imaging Single Photon Emitting Computed Tomographic (SPECT) radiopharmaceutical to gold nanoparticles will allow systemic targeting and imaging of cancer tissues simultaneously. In this study, gold nanoparticles (AuNPs) were prepared using Epigallocatechingallate (EGCG), loaded with doxorubicin (Dox), and characterized before and after doxorubicin conjugation. Cytotoxicity of EGCG-AuNPs and Dox-EGCG-AuNPs were evaluated against breast carcinoma (MCF-7) and hepatocellular carcinoma (HepG-2) cell lines demonstrating high cytotoxic effects of Dox-EGCG-AuNPs against both cell lines. Doxorubicin was radiolabeled with 99mTc and our new approach has optimized various labeling conditions resulting in a radiochemical yield of 93.5 ± 2.04%. Biodistribution of 99mTc-Dox-EGCG-AuNPs was studied in normal and tumor bearing mice following I.V. and intratumoral injections at different time intervals. Results showed high uptake of the intravenously injected 99mTc-Dox-EGCG-AuNPs in tumor tissue (22.45 %ID/g at 2 h). In addition, localized intratumoral injection of 99mTc-Dox-EGCG-AuNPs showed extremely high levels of uptake in tumor (80.22 %ID/g at 15 min) with high retention for extended periods post injection. Our results present prospects for the utility of 99mTc-Dox-EGCG-AuNPs as a multiplexed theranostic agent through SPECT imaging of tumor tissue and therapy through photothermal destruction of cancer tissue through the application of exogenous laser lights as well as through tyrosine phosphatases inhibitor (through EGCG), and topoisomerase II inhibitor (through doxorubicin) effects.